阿罗洛尔单药与联合非洛地平治疗慢性肾功能不全合并高血压的疗效比较

To monotherapy compared with the united arotinolol felodipine treatment of chronic renal insufficiency with hypertension efficacy and safety

目的比较阿罗洛尔单药与联合非洛地平治疗慢性肾功能不全合并高血压的疗效与安全性。方法 23例慢性肾功能不全合并高血压患者,随机分为阿罗洛尔组(单药组,起始剂量10 mg,2次/d,11例)和阿罗洛尔+非洛地平组(联合组,阿罗洛尔起始剂量10 mg,2次/d;非洛地平5 mg,1次/d,12例),共用药12周。观察高血压降压有效率和肾功能改善情况。结果两组患者经治疗后,两组患者收缩压与舒张压治疗后均有明显下降,差异有统计学意义(P<0.05),联合组患者血压下降更为显著。Scr(血肌酐)较治疗前下降,两组eGFR均有所提高,与治疗前比较差异均有统计学意义,而与单药组比较,联合组eGFR提高幅度更大,差异有统计学意义(P<0.05)。两组均无严重不良反应。结论阿罗洛尔+非洛地平联合组能降低CRF患者的高血压,并能改善其肾功能,比阿罗洛尔单药使用,疗效更佳。

Objective To monotherapy compared with the united arotinolol felodipine treatment of chronic renal insufficiency with hypertension efficacy and safety. Methods 23 patients with chronic renal insufficiency with hypertension were randomly divided into arotinolol group （monotherapy group,initial dose of 10 mg, bid, 11 cases） and arotinolol ＋ felodipine group （combination group, starting dose of 10 mg, bid; felodipine 5 mg, qd, 12 patients）, a total of 12 weeks of treatment. Observed blood pressure of hypertension and renal function efficiently improve the situation. Results Two groups of patients after treatment, systolic and diastolic blood pressure two groups were significantly decreased after treatment, the difference was statistically significant （ P 〈 0. 05 ） , the combination group were more significant decrease in blood pressure. Scr than before treatment, both groups were improved eGFR, compared with before treatment differences were statistically significant. Compared with the single drug in the combination group eGFR greater margin of increase, the difference was statistically significant （P 〈 O. 05 ）. There were no serious adverse events. Conclusion Arotinolol ＋ felodipine combined group could reduce blood pressure in patients with CRF, and can improve the renal function, better than arotinolol monotherapy.